The Pharmaceutical Research and Manufacturers of America has waded into the mifepristone controversy by filing an amicus brief – along with other industry stakeholders – asking for a reversal of a lower court decision in Alliance for Hippocratic Medicine v. the U.S. Food and Drug Administration. More than 250 congressional Democrats have also filed a brief urging an appeals